Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products (1) Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage Readouts Robust Late‑Stage R&D Pipeline, On Track to Start ~20 Key Pivotal Studies in 2026 …